Showcasing our Patented Inventions in Asia Summit on Global Health 2025

Lutetium-177 DOTATATE PRRT—a standard treatment for advanced neuroendocrine tumors—often causes severe gastrointestinal side effects (nausea, vomiting, diarrhea), likely due to co-infusion with kidney-protective amino acids.

Our Patented Solution

A novel administration platform that safely delivers Lutetium-177 DOTATATE/DOTATOC PRRT, reducing side effects while maintaining efficacy. Proven in real-world use with 20+ patients.

Our invention has already obtained Hong Kong SAR, China, Japan, Australia, Thailand, Korea, Malaysia, and Singapore.

In particular, our novel administrative platform has been commented as innovative and creative by China National Intellectual Property Administration (CNIPA).

Licensing and Approval for Release to the Market

We are currently applying for license and approval from Department of Health in Hong Kong and subsequent approval in Greater Bay Area.

Our groundbreaking platform was visited by the Shanghai Science and Technology Commissioner in the Asia Summit on Global Health 2025.

Introducing our platform to the Shanghai Science and Technology Commissioner by L'Ord'invent Limited Managing Director Prof Victor Lee.